---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026403"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:35:18.590389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity

## Summary
- CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.
- Economic modeling shows up to $895M savings for private payers, $379M for Medicare if used in 2022 standard of care.
- Clinical performance: 92% sensitivity, 87% specificity, 88% accuracy in nodules ≤20 mm.
- Case studies report Stage 1A detection when PET/CT, serum markers, and risk models failed.
- Study authored by BAMC and VA pulmonologists, supporting integration into VA standard of care.

## SEC filing metadata
- accession: 0001641172-25-026403
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000164117225026403/0001641172-25-026403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000164117225026403/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026403
- JSON: https://secwatch.observer/filing/0001641172-25-026403.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.